UnknownPHASE2, PHASE3NCT02882477

Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy

Studying Early-onset X-linked optic atrophy

Last synced from ClinicalTrials.gov May 8, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Hadassah Medical Organization
Principal Investigator: David Zangen, Professor
Head of pediatric endocrinology department
Intervention: Deferiprone(drug)
Enrollment: 20 enrolled
Eligibility: 3 years · All sexes
Timeline: 2016 – 2018

Study locations (1)

Hadassah medical center, Jerusalem, Israel

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02882477 on ClinicalTrials.gov

← Back to all trials